Ginger (Zingiber officinale)

Proven antiemetic for chemotherapy-induced nausea with strong evidence from multiple RCTs

Key Points

• Ginger root extract (500–1,000 mg/day) significantly reduces CINV severity and duration in multiple RCTs, particularly acute nausea on Day 1.
• Active constituents — gingerols and shogaols — antagonize 5-HT3 receptors and substance P (NK1), the same targets as ondansetron and aprepitant.
• Most beneficial as an adjunct to standard antiemetics rather than as monotherapy; does not replace ondansetron/aprepitant but enhances their effect.
• Also effective for postoperative nausea, motion sickness, and pregnancy-induced nausea.
• Inhibits platelet aggregation at high doses; avoid >2 g/day within 2 weeks of surgery.
• Highly palatable preparation options (crystallized ginger, ginger tea, capsules) enhance compliance.

Mechanism of Action

Ginger root (Zingiber officinale) contains a complex of bioactive phytochemicals — primarily gingerols (6-gingerol, 8-gingerol, 10-gingerol) in fresh root and shogaols (formed on drying/heating) in dried preparations. These compounds exert antiemetic effects through multiple complementary mechanisms. The primary antiemetic mechanism is 5-HT3 receptor antagonism in the GI tract and central vagal afferents — the same target as ondansetron and other setrons. Shogaols also antagonize substance P/NK1 receptors, which is the mechanism of aprepitant. This dual action on both the serotonergic and…

Clinical Evidence for CINV

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most distressing treatment-related side effects, and ginger has been evaluated in more than 20 clinical trials in this context. **Landmark Trials:** Ryan et al. (Support Care Cancer, 2012) — the largest trial, n=576, across multiple NCI-cooperative group sites: ginger supplementation (0.5 g or 1.0 g/day × 6 days beginning 3 days before each chemotherapy cycle, in addition to standard 5-HT3 antagonist + dexamethasone) significantly reduced acute nausea severity. The 0.5 g and 1.0 g doses outperformed placebo; the 1.5 g dose…

Other Applications in Cancer Care

Beyond CINV, ginger has evidence across several other symptom domains relevant to oncology patients: **Cancer-Related Fatigue:** A phase III trial (Zick et al., JCO 2018) found that ginger supplementation (800 mg/day) significantly reduced fatigue in breast cancer survivors — particularly morning fatigue. The proposed mechanism involves COX-2-mediated inflammatory pathway suppression and mitochondrial biogenesis support. **Arthralgia from Aromatase Inhibitors:** A pilot trial (Citronberg et al.) found that ginger 500 mg twice daily reduced AI-associated joint pain scores, consistent with its…